

Arterial stiffness: clinical implications and its role in cardiovascular disease

연세대학교 심장혈관병원

심장내과

최 동 훈

Arterial stiffness


- **Definition and pathophysiology of arterial stiffness**
- Association of arterial stiffness with cardiovascular disease
- Treatment of arterial stiffness

Arteriosclerosis is


= The hardening of the arteries

Aortic stiffness


Young adults



Older adults



Pathogenesis of arterial stiffness




Young normal aorta



Old stiff aorta




Young normal aorta



Resistance
artery

Old stiff aorta




Resistance
artery

Young normal aorta




Resistance
artery




Old stiff aorta


Resistance
artery




Young normal aorta



Old stiff aorta




Pressure during systole is a major determinant of myocardial O₂ requirement



Efficient arterial system

Pressure during diastole is a major determinant of CBF



Inefficient arterial system

Index of arterial stiffness

- Compliance

$$= \Delta D / \Delta P \text{ (cm/mmHg)}$$

Absolute diameter (or area) change for a pressure increment

- Distensibility

$$= \Delta D / \Delta P \cdot D_{\text{baseline}} \text{ (mmHg}^{-1} \text{)}$$

Relative diameter (or area) change for a pressure increment

- Young's Elastic Modulus

$$= \Delta P \cdot D / \Delta D \cdot h \text{ (mmHg/cm)}$$

- Beta index (Stiffness index)


$$= \ln(P_s/P_d) / [(D_s - D_d) / D_d]$$

- Pulse wave velocity (cfPWV, baPWV)


$$= \text{Distance} / \Delta \text{Time delay (cm/sec)}$$

Speed of travel of the pulse along an arterial segment


**Local
Stiffness**



Augmentation index = $\frac{P2-P1}{\text{Pulse pressure}}$



Relationship of aortic PWV (catheter method) and baPWV




Arterial stiffness

- Definition and pathophysiology of arterial stiffness
- **Association of arterial stiffness with cardiovascular disease**
- Treatment of arterial stiffness

Recent change in paradigm

Arterial stiffness and systolic hypertension is a normal aging process. You don't need to treat it




**Arterial stiffness is an independent risk factor
For adverse cardiovascular prognosis**

Arterial Stiffness

- **SBP** as a more **informative CV risk factor** in patients **older than 50 years**
- **PP** is an independent **marker of CV risk**
- In **subjects > 50 years** of age, **arterial stiffness** becomes the **main determinant of increased SBP and PP**

Pulse Pressure Predicts Risk Best In Older Hypertensives A Meta-Analysis



Blacher et al. Arch Intern Med. 2000;160

Anglo-Scandinavian
ascot
Cardiac Outcomes Trial

CAFÉ



**Differential Impact of Blood Pressure-Lowering Drugs on
Central Arterial Pressure Influences Clinical Outcomes -
Principal Results of the Conduit Artery Function Evaluation
(CAFÉ) Study in ASCOT**

Objects of CAFÉ study


● **Primary Objective**

- Whether different blood pressure-lowering regimens in ASCOT (atenolol+ thiazide versus amlodipine+ perindopril) make differential effects on central aortic pressures and hemodynamics

● **Secondary Objective**



- Whether central aortic pressures are an important determinant of clinical outcomes in ASCOT

CAFÉ Study Design




- >70% of ASCOT patients at 5 study centers recruited
- 80% of patients had > 1 tonometry measurement
- Average 3.4 tonometry measurements/patients
- Average follow up after first tonometry measurement was 3 years

Pulse Wave Analysis: Augmentation index



Radial a.


Pressure transfer function
(Degree of amplification)



Aorta

Radial artery pulse wave analysis

- Radial artery pulse wave
 - Radial artery applanation tonometry
 - Millar Tonometer
 - Pulse wave analysis
 - ⇒ Derived Central aortic pressure
 - SphygmoCor



Mean Proportion of Time(%) on BP Lowering Medication by Treatment Group*

	Year 1	All Study
Randomized to Amlodipine		
Amlodipine	90.0	80.7
Perindopril	56.0	66.7
Amlodipine + Perindopril	47.8	55.5
Randomized to Atenolol		
Atenolol	88.1	73.5
Bendroflumethiazide	69.8	74.2
Atenolol + Bendroflumethiazide	60.2	59.6


**from time of randomization into ASCOT*

- Monotherapy : Atenolol; 3.5% Amlodipine; 7%
- Average number of BP lowering drugs/patients: 2.2

Hemodynamic Data

Parameter	Atenolol	Amlodipine	Difference (Atenolol- Amlodipine)	Statistics t-test(P)
Brachial SBP (mm Hg)	133 (133, 134.7)	133.2 (132.5, 133.8)	0.7 (-0.4, 1.7)	0.2
Brachial DBP (mm Hg)	78.6 (78.1, 79.1)	76.9 (76.4, 77.4)	1.6 (0.9, 2.4)	<.0001
Brachial PP (mm Hg)	55.3 (54.6, 56)	56.2 (55.6, 56.9)	-0.9 (-1.9, 0)	.06
Heart rate (BPM)	58.6 (58, 59.2)	69.3 (68.6, 69.9)	-10.7 (-11.5, -9.8)	<.0001


Hemodynamic Data - Example



- Atenolol Group
 - Broader peripheral waveform
 - More prominent late systolic peak in central aortic waveform


Primary outcome

Brachial and Central Aortic Systolic Blood Pressure (+ 95% CI)




Atenolol	86	243	324	356	445	372	462	270	339	128	85	1031
Amlodipine	88	248	329	369	475	406	508	278	390	126	101	1042

Difference Between Brachial and Central Aortic Systolic BP by Treatment Arm



Atenolol	86	243	324	356	445	372	462	270	339	128	85	1031
Amlodipine	88	248	329	369	475	406	508	278	390	126	101	1042


Brachial and Central Aortic Pulse Pressure by Treatment Arm



Atenolol	86	243	324	356	445	372	462	270	339	128	85	1031
Amlodipine	88	248	329	369	475	406	508	278	390	126	101	1042



Pulse Wave Velocity

- Pulse wave travels faster through the stiffer artery.




Pulse Wave Analysis & AI

- Pulse wave travels faster through the stiffer artery.



Augmentation Index (%) by Treatment Arm




Atenolol	86	243	324	356	445	372	462	270	339	128	85	1031
Amlodipine	88	248	329	369	475	406	508	278	390	126	101	1042

Results summary

- Atenolol-based therapy associated with higher Central aortic systolic pressure and higher central aortic pulse pressure, despite similar brachial pressures, when compared with amlodipine-based therapy
- AI (central aortic pressure wave attributable to wave reflection) increased by atenolol-based therapy compared with amlodipine-based therapy

Secondary Endpoint regarding central aortic hemodynamic parameters and clinical outcomes



Atenolol	9639	8808	8455	8118	6965
Amlodipine	9618	8692	8259	7872	6710



Impact of Blood Pressure and Central Aortic Hemodynamics on Clinical Outcomes in the CAFÉ Study (Hazard/10 mm Hg)

Updated Cox proportional hazard model for the composite endpoint,
unadjusted

Factor	χ^2	P	HR	CI
Peripheral PP	21.0	<.0001	1.21	1.12-1.30
Central PP	17.8	<.0001	1.20	1.11-1.30
Augmentation	7.10	.008	1.22	1.06-1.4
P ₁ height	19.0	<.0001	1.37	1.20-1.54

Discussion

- Higher Central aortic systolic and pulse pressure may result from increased pressure wave reflection
- Mechanisms of Differences in aortic systolic pressure wave reflections
 - Arterial pulse wave velocity (x)
 - Pressure wave reflection site
 - Relative vasoconstriction
 - Small artery remodeling
 - Timing of systolic ejection resulting from differences in heart rate



CAFÉ study Conclusion

- Despite similar brachial systolic blood pressure, amlodipine + perindopril-based treatment more effective than atenolol+thiazide-based treatment at lowering central aortic systolic blood pressure and central aortic pulse pressure
- Central aortic pressure may be an important independent determinant of clinical outcomes
- Results of the CAFÉ study suggest that the “central aortic blood pressure hypothesis” is a plausible mechanism to explain the better clinical outcomes for hypertensive patients treated with amlodipine+perindopril-based therapy in ASCOT

Beyond brachial blood
pressure lowering effect!!